ClinicalTrials.gg

Chronic Cough clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 142 studies for Chronic Cough across more than 10 countries. 39 are recruiting or about to start. 109 of them are mainly about Chronic Cough (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Status

Completed
73
Recruiting
30
Status unknown
16
Terminated
10
Not yet recruiting
9
Active, not recruiting
3

Phase

Phase 2
35
Phase 3
14
Phase 1
12
Phase 4
7
Early Phase 1
5

Where

United States
44
United Kingdom
36
China
25
Canada
22
Poland
13
Czechia
9

Who develops what

Add Chronic Cough to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 4 programs from 4 companies, 4 with this as their studies’ main aim; 1 with a live phase 3 study; 3 primary completions in the next 12 months. Compare GlaxoSmithKline and Trevi Therapeutics here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 4 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jan 2027 est.SC0032 · Sensory Cloud, Inc. · Phase 2 main aimNCT07690059 A Study to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Cough — primary endpoint: Difference in mean % change from baseline in 24-hour cough frequency using the mean of Days -8 to -2 for last 7 days of baseline vs the mean of Days 13-19 last 7 days of the treatment period, using the HYFE continuous cough monitor). · 60 enrolled
  • 27 Aug 2027 est.camlipixant · GlaxoSmithKline · Phase 3 main aimNCT07650084 A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension — primary endpoint: 24-Hour Cough Frequency · 75 enrolled
  • Sep 2027 est.Nalbuphine · Trevi Therapeutics · Phase 2 main aimNCT07671924 The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) — primary endpoint: Relative Change From Baseline in 24-hour Cough Frequency at Week 6 · 100 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Chronic Cough studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Opioids 2 open

Coming up

9studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 9, phase 3 first

Who these studies take

Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 11 (37%) stop at 75 or younger. 3 (10%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 5 (17%) take healthy volunteers.

Recruiting studies that take each age, of 30
AgeWomenMen
102 (7%)2 (7%)
1824 (80%)24 (80%)
3027 (90%)27 (90%)
4027 (90%)27 (90%)
5027 (90%)27 (90%)
6526 (87%)26 (87%)
7522 (73%)22 (73%)
8514 (47%)14 (47%)

Across all 142 studies, recruiting or not: 32% stop at 75 or younger and 17% at 65; 11% take children; 1% are for women only and 1% for men only; 22% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Chronic Cough studies take

Of 25 phase 2 interventional studies under Chronic Cough, half reached primary completion within 11 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 211 mo10–21 · 25 studies——
Interventional, no phase20 mo7–48 · 21 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 142. Browse all 142 → or search them.